Iterum Therapeutics presents sulopenem for uUTI treatment review by FDA, with decision expected by October 25, 2024.

Iterum Therapeutics will present its first compound, sulopenem, at the H.C. Wainwright Global Investment Conference from September 9-11, 2024. The FDA is reviewing sulopenem as a treatment for uncomplicated urinary tract infections (uUTIs) but has raised concerns about potential misuse and its efficacy against antimicrobial-resistant strains. The FDA's decision on approval is expected by October 25, 2024. If approved, it would be the first oral penem antibiotic for uUTIs.

September 06, 2024
3 Articles

Further Reading